Voyager Therapeutics(VYGR) - 2025 Q2 - Quarterly Results

EXHIBIT 99.1 Voyager Reports Second Quarter 2025 Financial and Operating Results - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - 11 partnered programs with potential for $2.6B in development-stage milestone payments - LEXINGTON, Mass., August 6, 2025 -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quarter 2025 financial and operating results. "We f ...